Entrectinib can induce nerve cell damage by inhibiting PI3K-AKT and TGF-β signaling pathways
BackgroundThe tyrosine receptor kinase inhibitor (TRKi) entrectinib is used to treat neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumors and ROS1-positive patients. Despite its impressive efficacy against cancer, the clinical application is still limited by the central nervous...
Saved in:
| Main Authors: | Qingshan Tang, Jiachen Dong, Feng Zhang, Dan Zhao, Qi Yang, Jiayu Wen, Yuhao Sun, Jifu Wei, Zhixian Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1489210/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Polydatin-curcumin formulation alleviates CTD-ILD-like lung injury in mice via GABBR/PI3K/AKT/TGF-β pathway
by: Zhengju Zhang, et al.
Published: (2025-06-01) -
Covariation of scleral remodeling and PI3K/Akt signaling pathway in experimental myopia
by: Xiaomeng Li, et al.
Published: (2025-04-01) -
Hirudo extract ameliorates proliferative vitreoretinopathy by promoting autophagy and attenuating the THBS2/PI3K/Akt pathway
by: Hui Huang, et al.
Published: (2025-01-01) -
Recent advances in targeting obesity, with a focus on TGF-β signaling and vagus nerve innervation
by: Sahara John, et al.
Published: (2025-04-01) -
ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report
by: Qi Yujuan, et al.
Published: (2025-08-01)